Trading in Trill Impact’s portfolio company Cinclus Pharma commences on Nasdaq Stockholm
The Swedish biopharmaceutical company has successfully raised capital for Phase 3 clinical development
Cinclus Pharma Holding AB (publ) (“Cinclus Pharma”) is…
62,750€
-6,34%
Echtzeit-Aktienkurs Astrazeneca PLC (Spons. ADRs)
Bid:
Ask:
Nachrichten zur Astrazeneca PLC (Spons. ADRs) Aktie
AstraZenecas (AZN) Truqap Gets EU Nod for Breast Cancer
The European Commission approves AstraZenecas (AZN) Truqap in combination with Faslodex for ER-positive, HER2-negative advanced or metastatic breast cancer.…
AstraZenecas (AZN) Truqap Misses Endpoints in TNBC Study
AstraZenecas (AZN) phase III CAPItello-290 study evaluating Truqap plus chemotherapy in patients with locally advanced/metastatic triple-negative breast cancer fails to…
AstraZeneca gets FDA okay for Imfinzi for endometrial cancer
…
Imfinzi approved in the US for endometrial cancer
17 June 2024
Imfinzi plus chemotherapy approved in the US for
mismatch repair deficient advanced or recurrent endometrial cancer
Approval based on DUO-E…
AstraZenecas (AZN) Imfinzi Gets FDA Nod in Expanded Use
The FDA approves AstraZenecas (AZN) Imfinzi in combination with chemotherapy for treating mismatch repair deficient advanced/recurrent endometrial cancer based on…
AstraZeneca: The Price Upside Is Exhausted For Now (Rating Downgrade)
…
AstraZeneca CFO: Weve come a long way in our oncology portfolio
…
Insmed retains rights to brensocatib after talks with AstraZeneca end By Investing.com
Insmed retains rights to brensocatib after talks with AstraZeneca end…
FDA Expands AstraZenecas (AZN) Farxiga Label in Pediatric T2D
Following the label expansion, AstraZenecas (AZN) Farxiga is now approved to improve glycemic control in patients aged 10 years and…